

Tanya L Hoskin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10469895/publications.pdf>

Version: 2024-02-01

128
papers

4,979
citations

76196

40
h-index

102304

66
g-index

128
all docs

128
docs citations

128
times ranked

5752
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Academic Radiology</i> , 2022, 29, S145-S154.	1.3	31
2	Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning. <i>Npj Breast Cancer</i> , 2022, 8, 13.	2.3	6
3	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF κ B/p53 signaling in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 20.	2.3	9
4	Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. <i>Annals of Surgical Oncology</i> , 2022, 29, 4167-4179.	0.7	1
5	The breast tissue microbiome, stroma, immune cells and breast cancer. <i>Neoplasia</i> , 2022, 27, 100786.	2.3	9
6	ASO Visual Abstract: Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
7	Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2022, 29, 4740-4749.	0.7	8
8	ASO Author Reflections: Axillary Management in Mastectomy Patients with Limited Nodal Burden. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	1
9	ASO Visual Abstract: Contemporary Axillary Management in cT1-2N0 Breast Cancer with 1-2 Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
10	Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. <i>Annals of Surgical Oncology</i> , 2022, 29, 5747-5756.	0.7	9
11	Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5383-5386.	0.7	2
12	Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	1
13	Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 7769-7778.	0.7	2
14	Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. <i>Surgery</i> , 2021, 169, 644-648.	1.0	9
15	Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients: When to Stop?. <i>Annals of Surgical Oncology</i> , 2021, 28, 888-893.	0.7	5
16	Repeat Sentinel Lymph Node Surgery in Recurrent Breast Cancer: Peritumoral vs. Periareolar Injections. <i>Clinical Breast Cancer</i> , 2021, 21, 466-476.	1.1	0
17	Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB). <i>Annals of Surgical Oncology</i> , 2021, 28, 5867-5877.	0.7	10
18	Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 8729-8739.	0.7	6

#	ARTICLE	IF	CITATIONS
19	Decreasing the Use of Sentinel Lymph Node Surgery in Women Older than 70 Years with Hormone Receptor-Positive Breast Cancer and the Impact on Adjuvant Radiation and Hormonal Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 8766-8774.	0.7	4
20	ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 560-561.	0.7	1
21	Use of the Twelve-Gene Recurrence Score for Ductal Carcinoma in Situ and Its Influence on Receipt of Adjuvant Radiation and Hormonal Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 4294-4303.	0.7	4
22	Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 1-9.	0.7	0
23	Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 55-61.	1.1	4
24	Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 4795-4801.	0.7	55
25	Performance and Clinical Utility of Models Predicting Eradication of Nodal Disease in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy by Tumor Biology. <i>Annals of Surgical Oncology</i> , 2020, 27, 4678-4686.	0.7	4
26	Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast Biopsy. <i>Cancer Prevention Research</i> , 2020, 13, 967-976.	0.7	9
27	Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 51.	2.2	11
28	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1409-1418.	0.8	64
29	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor I±. <i>Clinical Cancer Research</i> , 2020, 26, 2986-2996.	3.2	17
30	Adolescents and Young Adults with Breast Cancer have More Aggressive Disease and Treatment Than Patients in Their Forties. <i>Annals of Surgical Oncology</i> , 2019, 26, 3920-3930.	0.7	65
31	Mastectomy and immediate breast reconstruction in the elderly: Trends and outcomes. <i>Surgery</i> , 2019, 166, 709-714.	1.0	30
32	Effect of Surgery Type on Time to Adjuvant Chemotherapy and Impact of Delay on Breast Cancer Survival: A National Cancer Database Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3240-3249.	0.7	46
33	Outcomes of >â€%1300 Nipple-Sparing Mastectomies with Immediate Reconstruction: The Impact of Expanding Indications on Complications. <i>Annals of Surgical Oncology</i> , 2019, 26, 3115-3123.	0.7	26
34	Bioinformatics and DNA-extraction strategies to reliably detect genetic variants from FFPE breast tissue samples. <i>BMC Genomics</i> , 2019, 20, 689.	1.2	37
35	Hyaline fibrous involution of breast lobules: a histologic finding associated with germline BRCA mutation. <i>Modern Pathology</i> , 2019, 32, 1263-1270.	2.9	1
36	ASO Author Reflections: A Statistical Caution Regarding Missing Clinical Stage in the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2019, 26, 569-570.	0.7	2

#	ARTICLE	IF	CITATIONS
37	Contralateral Axillary Metastases in Breast Cancer: Stage IV Disease or a Locoregional Event?. American Surgeon, 2019, 85, 1391-1396.	0.4	8
38	Lessons Learned Regarding Missing Clinical Stage in the National Cancer Database. Annals of Surgical Oncology, 2019, 26, 739-745.	0.7	24
39	Contralateral Axillary Metastases in Breast Cancer: Stage IV Disease or a Locoregional Event?. American Surgeon, 2019, 85, 1391-1396.	0.4	5
40	Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes. Clinical Breast Cancer, 2018, 18, e501-e506.	1.1	19
41	Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease. Cancer Prevention Research, 2018, 11, 113-119.	0.7	50
42	Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype. Annals of Surgical Oncology, 2018, 25, 482-493.	0.7	25
43	CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes. Breast Cancer Research and Treatment, 2018, 167, 649-658.	1.1	5
44	Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2018, 36, 1840-1846.	0.8	22
45	Management of the axilla in metaplastic breast carcinoma. Gland Surgery, 2018, 7, 200-206.	0.5	11
46	Association of Low Nodal Positivity Rate Among Patients With <i>ERBB2</i> -Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. JAMA Surgery, 2018, 153, 1120.	2.2	96
47	Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes. Annals of Surgical Oncology, 2018, 25, 2241-2248.	0.7	99
48	Effect of Primary Breast Tumor Location on Axillary Nodal Positivity. Annals of Surgical Oncology, 2018, 25, 3011-3018.	0.7	13
49	Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast. Annals of Surgical Oncology, 2018, 25, 3064-3068.	0.7	14
50	Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2018, 25, 2867-2874.	0.7	17
51	Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2018, 25, 2596-2602.	0.7	55
52	Longitudinal stability of fibromyalgia symptom clusters. Arthritis Research and Therapy, 2018, 20, 37.	1.6	7
53	Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer?. Annals of Surgical Oncology, 2017, 24, 614-617.	0.7	35
54	Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development. Clinical Cancer Research, 2017, 23, 3945-3952.	3.2	46

#	ARTICLE	IF	CITATIONS
55	Mastectomy and Immediate Breast Reconstruction for Cancer in the Elderly: A National Cancer Data Base Study. <i>Journal of the American College of Surgeons</i> , 2017, 224, 895-905.	0.2	26
56	Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 295-304.	1.1	68
57	Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 2518-2525.	0.7	17
58	Is axillary surgery beneficial for patients with adenoid cystic carcinoma of the breast?. <i>Journal of Surgical Oncology</i> , 2017, 116, 690-695.	0.8	14
59	National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 1242-1250.	0.7	51
60	Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer—A National Cancer Database study. <i>Npj Breast Cancer</i> , 2017, 3, 41.	2.3	18
61	Flat Epithelial Atypia on Core Biopsy and Upgrade to Cancer: a Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2017, 24, 3549-3558.	0.7	46
62	Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 133-143.	1.1	0
63	Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes. <i>Annals of Surgical Oncology</i> , 2017, 24, 3067-3072.	0.7	63
64	Breast Cancer-Related Lymphedema Risk is Related to Multidisciplinary Treatment and Not Surgery Alone: Results from a Large Cohort Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2972-2980.	0.7	118
65	Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2989-2998.	0.7	9
66	NanoString-based breast cancer risk prediction for women with sclerosing adenosis. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 641-650.	1.1	10
67	Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice. <i>Annals of Surgical Oncology</i> , 2017, 24, 2881-2888.	0.7	52
68	Using Size and Grade to Identify Women Aged 70 Years with Endocrine-Responsive Breast Cancer at Low Risk of Nodal Positivity. <i>Annals of Surgical Oncology</i> , 2017, 24, 557-558.	0.7	1
69	Outcomes and feasibility of nipple-sparing mastectomy for node-positive breast cancer Patients. <i>American Journal of Surgery</i> , 2017, 213, 810-813.	0.9	9
70	Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 418-424.	0.7	58
71	Contemporary operative management of T4 breast cancer. <i>Surgery</i> , 2016, 160, 1059-1069.	1.0	8
72	Validation of the CPS-Â-ÂEG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 3206-3211.	0.7	10

#	ARTICLE	IF	CITATIONS
73	Contralateral Prophylactic Mastectomy for Women with T4 Locally Advanced Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3365-3370.	0.7	7
74	Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. <i>Cancer</i> , 2016, 122, 2971-2978.	2.0	48
75	The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. <i>Scientific Reports</i> , 2016, 6, 30751.	1.6	299
76	Use of immediate breast reconstruction and choice for contralateral prophylactic mastectomy. <i>Surgery</i> , 2016, 159, 1199-1209.	1.0	39
77	Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3232-3238.	0.7	46
78	Natural history of age-related lobular involution and impact on breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 423-430.	1.1	29
79	Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing. <i>Annals of Surgical Oncology</i> , 2016, 23, 72-77.	0.7	14
80	Patients With Fibromyalgia Have Significant Autonomic Symptoms But Modest Autonomic Dysfunction. <i>PM and R</i> , 2016, 8, 425-435.	0.9	22
81	Perceived dyscognition reported by patients with fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S48-54.	0.4	5
82	Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER2 positive patients presenting with clinically node-negative disease. <i>Journal of Surgical Oncology</i> , 2015, 112, 453-457.	0.8	5
83	ER β Expression and Breast Cancer Risk Prediction for Women with Atypias. <i>Cancer Prevention Research</i> , 2015, 8, 1084-1092.	0.7	16
84	Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors. <i>Annals of Surgical Oncology</i> , 2015, 22, 3369-3375.	0.7	10
85	Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 183-190.	1.1	12
86	Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer. <i>Neoplasia</i> , 2015, 17, 348-357.	2.3	3
87	Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case-control study from the Mayo Benign Breast Disease Cohort. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 89-97.	1.1	13
88	Impact of Reconstruction and Reoperation on Long-Term Patient-Reported Satisfaction After Contralateral Prophylactic Mastectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 401-408.	0.7	55
89	Frequency of diagnosis of cancer or high-risk lesion at operation for pathologic nipple discharge. <i>Surgery</i> , 2015, 158, 988-995.	1.0	13
90	Expanded Indications and Improved Outcomes for Nipple-Sparing Mastectomy Over Time. <i>Annals of Surgical Oncology</i> , 2015, 22, 3317-3323.	0.7	116

#	ARTICLE	IF	CITATIONS
91	Evaluation of the Aromatase Inhibition Potential of Freeze-Dried Grape Powder. <i>Journal of Dietary Supplements</i> , 2015, 12, 373-382.	1.4	2
92	The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women: A Pilot Study. <i>Journal of Dietary Supplements</i> , 2014, 11, 184-197.	1.4	8
93	Randomized Trial of Drain Antisepsis After Mastectomy and Immediate Prosthetic Breast Reconstruction. <i>Annals of Surgical Oncology</i> , 2014, 21, 3240-3248.	0.7	13
94	Risk Factors Associated with Breast Lymphedema. <i>Annals of Surgical Oncology</i> , 2014, 21, 1202-1208.	0.7	48
95	Immune cell quantitation in normal breast tissue lobules with and without lobulitis. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 539-549.	1.1	65
96	Novel Factors to Improve Prediction of Nodal Positivity in Patients with Clinical T1/T2 Breast Cancers. <i>Annals of Surgical Oncology</i> , 2013, 20, 3286-3293.	0.7	19
97	Randomized Controlled Trial to Reduce Bacterial Colonization of Surgical Drains After Breast and Axillary Operations. <i>Annals of Surgery</i> , 2013, 258, 240-247.	2.1	63
98	A prospective study of breast lymphedema: frequency, symptoms, and quality of life. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 915-922.	1.1	47
99	Surgical Site Infection after Breast Surgery: Impact of 2010 CDC Reporting Guidelines. <i>Annals of Surgical Oncology</i> , 2012, 19, 4099-4103.	0.7	46
100	Predictors of Clinical Outcome in Fibromyalgia After a Brief Interdisciplinary Fibromyalgia Treatment Program: Single Center Experience. <i>PM and R</i> , 2012, 4, 257-263.	0.9	15
101	Histologic findings in normal breast tissues: comparison to reduction mammoplasty and benign breast disease tissues. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 169-177.	1.1	64
102	Contralateral Prophylactic Mastectomy: Long-Term Consistency of Satisfaction and Adverse Effects and the Significance of Informed Decision-Making, Quality of Life, and Personality Traits. <i>Annals of Surgical Oncology</i> , 2011, 18, 3110-3116.	0.7	98
103	Brief Interdisciplinary Treatment Program for Fibromyalgia. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2010, 89, 115-124.	0.7	28
104	Predicting Four or More Metastatic Axillary Lymph Nodes in Patients with Sentinel Node-Positive Breast Cancer: Assessment of Existent Risk Scores. <i>Annals of Surgical Oncology</i> , 2010, 17, 2884-2891.	0.7	3
105	Contralateral Prophylactic Mastectomy is Associated with a Survival Advantage in High-Risk Women with a Personal History of Breast Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 2702-2709.	0.7	135
106	Reply to S.L. Gomez et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e158-e158.	0.8	0
107	Conclusion about the association between valve surgery and mortality in an infective endocarditis cohort changed after adjusting for survivor bias. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 130-135.	2.4	30
108	Propensity score analysis with a time-dependent intervention is an acceptable although not an optimal analytical approach when treatment selection bias and survivor bias coexist. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 139-140.	2.4	6

#	ARTICLE	IF	CITATIONS
109	Incidence of Clinically Significant Seroma after Breast and Axillary Surgery. <i>Journal of the American College of Surgeons</i> , 2009, 208, 148-150.	0.2	56
110	Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node–positive breast cancer patients. <i>Cancer</i> , 2009, 115, 4064-4070.	2.0	31
111	Simple Prediction Models for Breast Cancer Patients with Solitary Positive Sentinel Nodes—are they Valid?. <i>Breast Journal</i> , 2009, 15, 610-614.	0.4	6
112	Sentinel node positive breast cancer patients who do not undergo axillary dissection: Are they different?. <i>Surgery</i> , 2008, 143, 641-647.	1.0	31
113	Open repair of juxtarenal aortic aneurysms (JAA) remains a safe option in the era of fenestrated endografts. <i>Journal of Vascular Surgery</i> , 2008, 47, 695-701.	0.6	159
114	Common iliac artery aneurysm: Expansion rate and results of open surgical and endovascular repair. <i>Journal of Vascular Surgery</i> , 2008, 47, 1203-1211.e2.	0.6	181
115	Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. <i>American Journal of Surgery</i> , 2008, 196, 228-233.	0.9	76
116	Dysphagia in Inclusion Body Myositis. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2008, 87, 883-889.	0.7	94
117	The Impact of Valve Surgery on 6-Month Mortality in Left-Sided Infective Endocarditis. <i>Circulation</i> , 2007, 115, 1721-1728.	1.6	119
118	Early complications and long-term outcome after open surgical treatment of popliteal artery aneurysms: Is exclusion with saphenous vein bypass still the gold standard?. <i>Journal of Vascular Surgery</i> , 2007, 45, 706-715.e1.	0.6	170
119	Dysphagia in Inflammatory Myopathy: Clinical Characteristics, Treatment Strategies, and Outcome in 62 Patients. <i>Mayo Clinic Proceedings</i> , 2007, 82, 441-447.	1.4	161
120	Factors affecting outcomes of open surgical repair of pararenal aortic aneurysms: A 10-year experience. <i>Journal of Vascular Surgery</i> , 2006, 43, 921-928.e1.	0.6	171
121	Temporal Trends in Infective Endocarditis. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 3022.	3.8	309
122	CT Fluoroscopy–guided Biopsy of the Lung or Upper Abdomen with a Breath-hold Monitoring and Feedback System: A Prospective Randomized Controlled Clinical Trial. <i>Radiology</i> , 2005, 237, 701-708.	3.6	67
123	Noninvasive measurement of aortic aneurysm sac tension with vibrometry. <i>Journal of Vascular Surgery</i> , 2005, 42, 963-971.	0.6	9
124	Most Patients with Abdominal Aortic Aneurysm Are Not Suitable for Endovascular Repair Using Currently Approved Bifurcated Stent-Grafts. <i>Vascular and Endovascular Surgery</i> , 2004, 38, 401-412.	0.3	73
125	Endovascular Repair of Abdominal Aortic Aneurysms: In Response. <i>Mayo Clinic Proceedings</i> , 2004, 79, 570-571.	1.4	0
126	Perioperative complications and early outcome after endovascular and open surgical repair of abdominal aortic aneurysms. <i>Journal of Vascular Surgery</i> , 2004, 39, 497-505.	0.6	147

#	ARTICLE	IF	CITATIONS
127	Endovascular Repair of Abdominal Aortic Aneurysms: Initial Experience With 100 Consecutive Patients. Mayo Clinic Proceedings, 2003, 78, 1234-1242.	1.4	34
128	Intermittent-Mode CT Fluoroscopyâ€“guided Biopsy of the Lung or Upper Abdomen with Breath-hold Monitoring and Feedback: System Development and Feasibility. Radiology, 2003, 229, 906-912.	3.6	25